The global Artificial Intelligence (AI) in Cancer market size is predicted to grow from US$ 2353 million in 2025 to US$ 8085 million in 2032; it is expected to grow at a CAGR of 19.3% from 2026 to 2032.

Artificial Intelligence (AI) in Cancer refers to the application of machine learning, deep learning, and data-driven computational models across the oncology care continuum to support cancer screening, diagnosis, treatment planning, and outcome prediction. AI systems in oncology analyze large volumes of heterogeneous data, including medical imaging, digital pathology slides, genomic and multi-omics data, and real-world clinical records, to detect patterns that exceed human cognitive limits. In clinical practice, these solutions function primarily as decision-support tools, improving diagnostic accuracy, standardizing interpretation, accelerating workflows, and enabling more personalized treatment strategies. Rather than replacing oncologists, AI augments clinical expertise by reducing variability and supporting earlier and more consistent cancer detection and management.

From a multi-angle classification and parameterization perspective, the market can be segmented by clinical application stage (screening and early detection, diagnosis and classification, treatment planning, therapy monitoring, and prognosis), by data modality (imaging-based, pathology-based, genomics-based, clinical data-driven, or multimodal fusion), and by cancer type (lung, breast, colorectal, prostate, hematologic, and rare cancers). Additional parameters that differentiate solutions include sensitivity and specificity at defined clinical thresholds, explainability of AI outputs, integration with hospital IT systems, regulatory clearance status, and scalability across institutions and geographies.

The industry value chain begins upstream with data generation and infrastructure providers, including imaging equipment manufacturers, sequencing platforms, digital pathology scanners, and cloud computing services. Midstream players consist of AI oncology solution developers that curate datasets, train models, and package algorithms into regulated software or integrated platforms. Downstream customers include hospitals, cancer centers, diagnostic laboratories, pharmaceutical companies, and population-level screening programs, often adopting AI tools through enterprise licenses or software-as-a-service models.

From a profitability standpoint, AI in Cancer solutions typically exhibit gross margins in the 6585% range, reflecting their software-centric economics once development and regulatory costs are absorbed. Cloud-based platforms and AI-as-a-service models tend to achieve the highest margins, while device-embedded solutions trade some margin for faster adoption through OEM partnerships. Market growth is driven by rising cancer incidence, shortages of oncology specialists, increasing data complexity, and the shift toward precision medicine. Key trends include multimodal data integration, expansion from detection to outcome prediction, deeper OEM and hospital integration, and growing use of AI to support value-based oncology care.

Infinity Market Research newest research report, the Artificial Intelligence (AI) in Cancer Industry Forecast looks at past sales and reviews total world Artificial Intelligence (AI) in Cancer sales in 2025, providing a comprehensive analysis by region and market sector of projected Artificial Intelligence (AI) in Cancer sales for 2026 through 2032. With Artificial Intelligence (AI) in Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Artificial Intelligence (AI) in Cancer industry.

This Insight Report provides a comprehensive analysis of the global Artificial Intelligence (AI) in Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Artificial Intelligence (AI) in Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Artificial Intelligence (AI) in Cancer market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Artificial Intelligence (AI) in Cancer and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Artificial Intelligence (AI) in Cancer.

This report presents a comprehensive overview, market shares, and growth opportunities of Artificial Intelligence (AI) in Cancer market by product type, application, key players and key regions and countries.

Segmentation by Type:

    Medical Imagingbased AI
    Digital Pathologybased AI
    Genomics & Multi-omics AI
    Others
    Segmentation by AI Function Depth:
    Detection & Flagging
    Segmentation & Quantification
    Classification & Grading
    Prediction & Outcome Modeling
    Others
    Segmentation by Product Form & Commercial Model:
    Device-embedded AI Systems
    Standalone Software / SaaS Platforms
    AI-as-a-Service for Oncology
    Others

Segmentation by Application:

    Lung Cancer
    Breast Cancer
    Colorectal & GI Cancers
    Prostate & Urological Cancers
    Hematologic & Rare Cancers
    Others

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration.

    PathAI
    PaigeAI
    Lunit
    INFERVISION TECHNOLOGY
    Aidoc
    VUNO, Inc.
    ANNALISE-AI PTY LTD
    BioMind
    YITU Technology
    Shukun Technology
    Beijing Huiyi Huiying Medical Technology
    Shenzhen Keya Medical Technology
    Densitas
    Volpara
    Niramai
    MVision AI
    MammoScreen
    Perimeter Medical Imaging AI
    ICAD
    LungLifeAI
    Nanox.AI
    Varian Medical Systems
    Canon Medical
    GE Healthcare
    Philips